Henry Durivage Appointed Director of the Clinical Trials Office at Yale Cancer Center and the Yale Center for Clinical Investigation
For Immediate Release
Date: 01/07/10
Contact:
Renee Gaudette, (203) 436-8533, or renee.gaudette@yale.edu
New Haven, Conn. — Thomas J. Lynch, Jr., MD, Director of Yale Cancer Center, announced Henry Durivage, PharmD as Director of the Clinical Trials Office at the Center. Mr. Durivage is currently Director the Cancer Institute of New Jersey Oncology Group and Human Research Services.
“The expansion of clinical trial opportunities for our patients is a priority for Yale Cancer Center. We welcome Hank’s experience as a leader in clinical trial development and recruitment as we continue to expand the treatment options for our patients,” Lynch said.
Mr. Durivage’s new position will be accountable and responsible for successfully developing, promoting, implementing, and achieving the strategic plan for cancer clinical trials research at Yale. He will serve as an integral participant of the leadership team for the Yale Center for Clinical Investigation. The Clinical Trials Office provides the infrastructure to sustain translational research and support for oncology clinical trials conducted by Yale investigators.
Mr. Durivage completed his undergraduate education at the University of Nebraska and received his Doctor of Pharmacy from the University of Nebraska Medical Center College of Pharmacy.
Yale Cancer Center is one of a select network of 40 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Yale-New Haven Hospital and the Yale University School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.